# EndocrineAI - Diabetes & Thyroid Management Platform
## Venture Specification

**Document Version:** 1.0
**Date Created:** 2026-03-02
**Status:** GO - Pursue
**Agent Score:** 8.17/10

---

## Executive Summary

EndocrineAI is an AI-powered clinical decision support platform designed specifically for endocrinologists. The platform automates the interpretation of continuous glucose monitor (CGM) data, optimizes insulin dosing, predicts diabetes trends, analyzes thyroid ultrasounds for nodule classification, and streamlines endocrine workflow management.

**One-Liner:** AI-powered co-pilot for endocrinologists that predicts hypoglycemia before it happens and saves hours in CGM review.

---

## 1. Core Concept

EndocrineAI is a vertical AI platform for endocrinology that combines:

1. **CGM Interpretation Engine** - Automated analysis of 14-day continuous glucose monitoring data
2. **Insulin Dosing Optimizer** - ML-driven recommendations for basal, bolus, and correction factors
3. **Diabetes Trend Prediction** - Time-series forecasting for hypoglycemia and hyperglycemia events
4. **Thyroid Nodule Analyzer** - Computer vision for ultrasound classification and TI-RADS scoring
5. **Endocrine Workflow Suite** - EHR integration, patient tracking, and population health management

**Key Insight:** Endocrinologists spend 30-40% of their time manually reviewing CGM data. AI can automate this while providing predictive insights that humans cannot see.

---

## 2. Problem Statement

### 2.1 Market Size

| Segment | US Population | Growth |
|---------|---------------|--------|
| Type 2 Diabetes | 32M+ | Growing |
| Type 1 Diabetes | 2M+ | Growing |
| Pre-diabetes | 50M+ | Growing |
| Thyroid Nodules | 50M+ (50% adults) | Stable |
| Endocrinologists | 10,000 | Flat |

### 2.2 Pain Points

**For Endocrinologists:**
- **CGM Review Bottleneck:** 14 days × 288 readings/day = 4,032 data points per patient
- **Insulin Dosing Complexity:** Basal, bolus, carbohydrate ratios, correction factors, timing
- **Time Pressure:** Average patient visit = 15-20 minutes; CGM review alone can take 10+ minutes
- **Thyroid Nodule Risk Assessment:** Manual TI-RADS scoring is subjective and time-consuming
- **Reimbursement Pressure:** Shift to value-based care requires better outcomes documentation

**For Patients:**
- **Hypoglycemia Fear:** Nocturnal hypoglycemia is a leading cause of ER visits and mortality
- **Glycemic Variability:** Difficult to correlate with lifestyle factors
- **Insulin Burden:** Complex dosing regimens lead to errors and non-adherence
- **Thyroid Cancer Anxiety:** Most nodules are benign, but evaluation takes weeks

**For Healthcare Systems:**
- **Diabetes Complications:** $327B annually in US medical costs
- **Readmissions:** Poor glycemic control drives hospital readmissions
- **Specialist Shortage:** Endocrinologist shortages, especially in rural areas

---

## 3. Target Vertical

### 3.1 Primary Customers

**Adult Endocrinologists (7,000+ in US)**
- Focus: Type 2 diabetes, thyroid disorders
- Patient volume: 50-100 patients/week
- CGM adoption: 60%+ of patients

**Pediatric Endocrinologists (1,500+ in US)**
- Focus: Type 1 diabetes, growth disorders
- Patient volume: 30-60 patients/week
- CGM adoption: 80%+ of patients

**Diabetes Educators (20,000+ in US)**
- Certified Diabetes Care and Education Specialists (CDCES)
- High CGM usage, high patient touch frequency
- Key influencers in prescribing decisions

**Endocrinology Practices**
- Single-specialty groups (5-20 physicians)
- Hospital-employed practices
- Academic medical centers

### 3.2 Secondary Customers

**Primary Care Physicians**
- Manage 70% of diabetes patients
- Limited endocrinology training
- High referral potential

**Health Systems**
- Population health management
- Value-based care programs
- Remote patient monitoring

---

## 4. Why Now

### 4.1 Market Timing

| Factor | Trend | Evidence |
|--------|-------|----------|
| CGM Adoption | Accelerating | Dexcom G7, Libre 3 - insurance coverage expanding |
| Diabetes Prevalence | Growing | CDC: 1 in 3 Americans by 2050 |
| AI in Healthcare | Accepted | FDA AI/ML SaMD pathway established |
| Value-Based Care | Mandated | MIPS, APMs require outcome tracking |
| Workforce Shortage | Worsening | 10% endocrinologist deficit by 2030 |

### 4.2 Technology Readiness

**CGM Data Accessibility:**
- Dexcom API (public, OAuth)
- Abbott LibreView (developer program)
- Medtronic CareLink (API available)
- Apple HealthKit / Google Health Connect aggregation

**AI Model Maturity:**
- Time-series forecasting (Transformer architectures)
- Computer vision for medical imaging (validated in radiology)
- LLMs for report generation and summarization

**Regulatory Clarity:**
- FDA Software as a Medical Device (SaMD) framework
- AI/ML-based SaMD guidance (2021)
- Predetermined Change Control Plans (PCCP)

### 4.3 Competitive Landscape Dynamics

**Threat:**
- CGM manufacturers launching built-in analytics (Dexcom Clarity)
- Insulin pump companies adding predictive features

**Opportunity:**
- Device-specific analytics don't cross platforms
- No unified endocrine platform (CGM + thyroid + workflow)
- Manufacturers lack clinical workflow expertise
- Endocrinologists want platform-agnostic solutions

---

## 5. AI Advantage

### 5.1 Core AI Capabilities

**1. CGM Time-Series Analysis**
```
Input: 14 days × 288 readings = 4,032 glucose values
Features:
- Glucose pattern recognition (dawn phenomenon, postprandial spikes)
- Glycemic variability indices (CV, SD, TIR)
- Time-in-range optimization (70-180 mg/dL)
- Hypoglycemia pattern detection (<70, <54 mg/dL)
```

**2. Hypoglycemia Prediction**
```
Model: Temporal Fusion Transformer
Input Window: 6 hours of CGM + insulin + meals
Output: Probability of hypoglycemia in next 2 hours
Target: >0.80 AUC, <15% false alarm rate
Value: Life-saving, prevents ER visits
```

**3. Insulin Dosing Optimization**
```
Model: Reinforcement Learning + Clinical Rules
Inputs: CGM patterns, current regimen, carbohydrate intake
Outputs: Optimized basal rate, ICR, ISF
Constraints: Safety bounds, physician override
```

**4. Thyroid Nodule Classification**
```
Model: EfficientNet-B4 for ultrasound
Input: Thyroid ultrasound images
Output: TI-RADS score + malignancy probability + segmentation
Training: ACR TI-RADS atlas + labeled clinical data
```

**5. A1C Prediction**
```
Model: Gradient boosting on CGM features
Input: 14-day CGM metrics (mean glucose, TIR, CV)
Output: Predicted A1C with confidence interval
Accuracy: Target ±0.3% vs lab A1C
```

### 5.2 Technical Differentiation

| Feature | EndocrineAI | Device Analytics | EHR Built-ins |
|---------|-------------|------------------|---------------|
| Multi-device CGM | Yes | No | No |
| Insulin Optimization | Yes | Limited | No |
| Thyroid Ultrasound | Yes | No | No |
| Clinical Workflow | Yes | No | Limited |
| EHR Integration | Deep | None | Native |
| Specialty-Specific | Yes | No | No |

---

## 6. Viral Mechanism

### 6.1 Conference Strategy

**Primary Conferences:**
- ADA Scientific Sessions (June, 10,000+ attendees)
- ENDO (Endocrine Society Annual Meeting, March, 7,000+ attendees)
- ATTD (Advanced Technologies & Treatments for Diabetes, February)
- AAES (Association of Clinical Endocrinologists)

**Viral Demo:** "This AI predicted hypoglycemia 3 hours before it happened - and the patient was sleeping"

### 6.2 Word-of-Mouth Drivers

1. **Life-Saving Stories:** "Prevented nocturnal hypoglycemia" = patient gratitude
2. **Time Savings:** "Cut my CGM review time by 60%" = physician productivity
3. **Outcome Improvements:** "Improved TIR by 15% in my patient panel" = quality metrics
4. **Academic Validation:** Published abstracts = referral networks

### 6.3 Network Effects

**Practice-Level:** One physician adoption → practice-wide adoption (shared patient panel)

**Patient-Level:** Patients request "the AI that my friend uses"

**System-Level:** Academic center adoption → community referral pattern influence

**Educator Network:** Diabetes educators influence multiple physicians

---

## 7. Revenue Model

### 7.1 Pricing Tiers

| Tier | Monthly Fee | Patients Included | Features |
|------|-------------|-------------------|----------|
| Starter | $400 | 100 | CGM interpretation, trend prediction, basic reports |
| Professional | $800 | 250 | Full suite + insulin optimization + thyroid analysis |
| Enterprise | $2,500 | Unlimited | Multi-location + population health + API + dedicated support |

**Per-Patient Add-on:** $5 per AI-monitored patient/month (beyond included tiers)

**Implementation Fee:** $2,500 one-time (EHR integration, training)

### 7.2 Unit Economics

```
Customer Acquisition Cost (CAC): $250
- ADA/ENDO conferences: $150
- Digital marketing: $50
- Sales commission: $50

Average Revenue Per User (ARPU): $600/month (blended)
- Gross Margin: 85% (software, low variable cost)

Lifetime Value (LTV): $21,600 (36 months × $600)
- Assumption: 3-year retention (switching costs high)
- Churn: <5% annually after year 1

LTV:CAC Ratio: 86:1 (excellent)

Payback Period: <2 months
```

### 7.3 Revenue Projections

| Year | Practices | MRR | ARR | Cumulative |
|------|-----------|-----|-----|------------|
| Year 1 | 15 | $9,000 | $108,000 | $108,000 |
| Year 2 | 75 | $45,000 | $540,000 | $648,000 |
| Year 3 | 200 | $120,000 | $1,440,000 | $2,088,000 |
| Year 4 | 400 | $240,000 | $2,880,000 | $4,968,000 |
| Year 5 | 700 | $420,000 | $5,040,000 | $10,008,000 |

**Market Penetration Assumptions:**
- Year 1: 0.15% of 10,000 endocrinologists
- Year 3: 2% of endocrinologists
- Year 5: 7% of endocrinologists (realistic with distribution)

---

## 8. MVP in 8 Weeks

### 8.1 Development Plan

**Weeks 1-2: Foundation & Data**
- Partner with one endocrinology practice
- Set up CGM data pipeline (Dexcom API priority)
- Establish HIPAA-compliant infrastructure
- Collect initial dataset (50 patients × 14-day CGM)

**Weeks 3-5: Core AI Models**
- CGM pattern recognition (time-series CNN)
- Hypoglycemia prediction (LSTM/Transformer)
- Basic report generation (template-based)
- Web dashboard for visualization

**Weeks 6-7: Pilot & Validation**
- Deploy to partner practice
- 20-patient pilot study
- Collect: prediction accuracy, time savings, satisfaction
- Iterate on model performance

**Week 8: Refinement & Demo**
- Final model tuning
- Prepare ADA conference demo
- Create case studies
- Implement practice #2

### 8.2 Validation Metrics

| Metric | Target | Why |
|--------|--------|-----|
| Hypoglycemia Prediction AUC | >0.80 | Clinical utility threshold |
| Glucose Prediction MAE | <15 mg/dL | Acceptable error for dosing |
| CGM Review Time Savings | >50% | Productivity ROI |
| Physician Satisfaction | >4/5 | Adoption likelihood |
| Pilot Conversion | >1 practice | Product-market fit signal |

### 8.3 Go/No-Go Criteria

**GO if:**
- Hypoglycemia AUC >0.75
- 2+ practices commit to paid pilot
- Clear time-savings demonstrated

**NO-GO if:**
- Prediction AUC <0.70 (not clinically useful)
- Data access blocked by manufacturers
- Zero practice interest after demo

---

## 9. Tech Stack

### 9.1 Architecture

```
[CGM Devices] [EHR Systems] [Insulin Pumps]
      ↓             ↓              ↓
┌─────────────────────────────────────────┐
│           Ingestion Layer               │
│  - Dexcom API  - Epic FHIR  - Tidepool  │
└─────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────┐
│          Processing Layer               │
│  - Apache Kafka  - Spark  - PostgreSQL  │
└─────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────┐
│            AI/ML Layer                  │
│  - PyTorch Serving  - ONNX  - Scikit    │
└─────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────┐
│          Application Layer              │
│  - FastAPI  - React  - Python 3.11     │
└─────────────────────────────────────────┘
                 ↓
┌─────────────────────────────────────────┐
│           Frontend Layer                │
│  - React  - TypeScript  - Plotly        │
└─────────────────────────────────────────┘
```

### 9.2 Technology Choices

| Component | Technology | Rationale |
|-----------|------------|-----------|
| Backend | Python/FastAPI | ML-native, async, type safety |
| AI Framework | PyTorch | Research flexibility, production ready |
| Time-Series | PyTorch Forecasting | Specialized library |
| Computer Vision | MONAI + timm | Medical imaging focus |
| Database | PostgreSQL + TimescaleDB | Relational + time-series optimized |
| Cache | Redis | Session management, real-time data |
| Queue | Celery + Redis | Background tasks |
| Infrastructure | AWS (us-east-1) | HIPAA, mature healthcare ecosystem |
| Container | Docker + EKS | Scalability, isolation |
| Monitoring | Prometheus + Grafana | Health metrics |
| Logging | ELK Stack | Audit trails (HIPAA) |
| Frontend | React + TypeScript | Type safety, ecosystem |
| Charts | Plotly.js | Scientific visualization |

### 9.3 Data Architecture

**Raw Data Storage:**
- CGM readings: Time-series database (1 read/5min = 288/day/patient)
- Insulin events: Relational (timestamp, type, units)
- Meal logs: Relational (timestamp, carbs, estimation method)
- Thyroid images: Object storage (S3 with encryption)

**Feature Store:**
- Pre-computed features (TIR, CV, GMI, variability)
- Patient embeddings
- Aggregates for population health

**Model Registry:**
- Model versioning
- Training metadata
- Performance metrics over time

---

## 10. Risk Factors

### 10.1 Technical Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| CGM API access blocked | Medium | High | Direct partnerships, patient-directed data |
| Hypoglycemia prediction insufficient | Low | High | Ensemble methods, conservative thresholds |
| Thyroid ultrasound CV accuracy | Medium | Medium | Start with assistive (not diagnostic) |
| EHR integration complexity | High | Medium | FHIR standards, integration partners |
| Data security breach | Low | Critical | HIPAA audit, penetration testing, SOC 2 |

### 10.2 Business Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Manufacturer competition (built-in analytics) | High | Medium | Platform-agnostic, workflow focus |
| Insulin dosing liability | Medium | Critical | Decision support only, MD approval required |
| Slow physician adoption | Medium | High | Free pilots, academic validation |
| FDA clearance delays | Medium | High | SaMD pathway, start with non-regulated features |
| Reimbursement not covered | Medium | Medium | Focus on productivity ROI, not billing |

### 10.3 Competitive Risks

**Established Players:**
- **Dexcom Clarity:** CGM-specific, strong adoption
- **Glooko:** Diabetes data aggregation, payer relationships
- **Teladoc/Livongo:** Consumer-focused, employer channels

**New Entrants:**
- **Epic/Cerner:** Could build native analytics
- **Big Tech:** Apple/Google health initiatives

**Differentiation Strategy:**
- Specialty-specific (endocrinology, not general diabetes)
- Multi-device aggregation (platform-agnostic)
- Clinical workflow integration (not just analytics)
- Thyroid + diabetes in one platform

---

## 11. Competitive Analysis

### 11.1 Feature Comparison Matrix

| Feature | EndocrineAI | Dexcom Clarity | Glooko | Tidepool |
|---------|-------------|----------------|--------|----------|
| CGM Analysis | ✅ Multi-device | ✅ Dexcom only | ✅ Multi-device | ✅ Multi-device |
| Insulin Optimization | ✅ ML-based | ❌ | ❌ | ❌ |
| Hypoglycemia Prediction | ✅ | ❌ | ❌ | ❌ |
| Thyroid Ultrasound | ✅ | ❌ | ❌ | ❌ |
| EHR Integration | ✅ Deep | ❌ | ✅ Basic | ✅ Basic |
| Decision Support | ✅ Endocrine-specific | ❌ | ❌ | ❌ |
| Population Health | ✅ | ❌ | ✅ | ❌ |
| Specialty Focus | ✅ Endocrinology | ❌ General | ❌ General | ❌ General |

### 11.2 Positioning Statement

**For** endocrinologists managing complex diabetes and thyroid patients,
**Who need** to interpret vast amounts of CGM data and optimize treatment efficiently,
**Our product** is an AI-powered clinical decision support platform,
**That** automates CGM review, predicts hypoglycemia, and optimizes insulin dosing,
**Unlike** device-specific analytics or generic EHR tools,
**Our product** combines multi-device data, endocrine-specific AI, and workflow integration in one platform.

---

## 12. Go-to-Market Strategy

### 12.1 Launch Phases

**Phase 1: Pilot (Months 1-6)**
- 5 practices in academic medical centers
- Focus on CGM interpretation + hypoglycemia prediction
- Generate case studies, publish abstracts
- Pricing: Free (feedback in exchange)

**Phase 2: Early Adopters (Months 7-18)**
- 50 practices through ADA/ENDO conferences
- Full feature suite (insulin dosing + thyroid)
- Regional focus (diabetes belts: South, Midwest)
- Pricing: $400-800/month

**Phase 3: Expansion (Months 19-36)**
- Enterprise sales to health systems
- Population health modules
- Value-based care contracts (risk-sharing)
- Pricing: $2,500/month + % of savings

### 12.2 Sales Strategy

**Conference-Driven:**
- Demo booths at ADA, ENDO, ATTD
- "Hypoglycemia Prediction" live demos
- Abstract submissions (research credibility)

**Account-Based Marketing:**
- Target top 50 diabetes centers
- Personal outreach to department chairs
- Free pilot → paid conversion

**Digital Marketing:**
- Content: CGM interpretation case studies
- Webinars: "AI in Endocrinology"
- SEO: "CGM analysis tools", "insulin dosing calculator"

**Partnerships:**
- Diabetes education companies
- EHR vendors (app marketplace)
- Academic CME programs

### 12.3 Customer Success

**Onboarding (Week 1):**
- EHR integration setup
- Staff training (2 hours)
- First patient data load
- Customized alert configuration

**Ongoing:**
- Quarterly business reviews
- Model performance reports
- New feature webinars
- Clinical advisory board input

**Retention:**
- Switching costs: workflow integration, patient history
- Network effects: practice-wide adoption
- Continuous improvement: model updates quarterly

---

## 13. Regulatory Pathway

### 13.1 FDA Classification

**Initial Features (Non-Regulated):**
- CGM data visualization
- Retrospective pattern analysis
- Report generation
- Workflow tools

**Future Features (SaMD - Software as a Medical Device):**
- Hypoglycemia prediction → Class II
- Insulin dosing recommendations → Class II
- Thyroid nodule classification → Class II

### 13.2 Regulatory Strategy

**Phase 1: Market Entry (No FDA Required)**
- Launch as "retrospective analysis tool"
- Position as decision support, not diagnosis
- Clear labeling: "For informational purposes"

**Phase 2: FDA Submission (Month 12-18)**
- 510(k) pathway (predicate: existing CGM analytics)
- De Novo for novel features (hypoglycemia prediction)
- PCCP (Predetermined Change Control Plan) for iterative improvement

**Phase 3: Reimbursement (Month 24+)**
- CPT code coverage
- Medicare coverage determination
- Commercial payer negotiations

---

## 14. Team Requirements

### 14.1 Core Team

**Technical:**
- CEO/Co-founder: Healthcare AI background
- CTO/Co-founder: ML/time-series expertise
- ML Engineer: PyTorch, time-series forecasting
- Full-Stack Engineer: Python/React, healthcare integrations
- Clinical Informatician: EHR integration, FHIR

**Clinical:**
- Medical Director: Board-certified endocrinologist (part-time)
- Clinical Advisors: 3-5 practicing endocrinologists
- Diabetes Educator: CDCES certification

**Operations:**
- Product Manager: Healthcare SaaS experience
- Customer Success: Clinical background
- Regulatory Affairs: FDA SaMD experience

### 14.2 Advisors Needed

- **Endocrinology:** Academic department chair
- **Diabetes Technology:** Industry connections
- **FDA Regulatory:** SaMD submission experience
- **Healthcare Sales:** Practice sales experience
- **CGM Industry:** Device manufacturer relationships

---

## 15. Funding Requirements

### 15.1 Use of Funds

**Pre-Seed: $500K (Months 1-12)**
- Team: 3 founders + 1 engineer ($350K)
- Infrastructure: AWS, HIPAA compliance ($50K)
- Clinical partnerships: Pilot stipends ($50K)
- Legal: IP, regulatory prep ($25K)
- Conference presence: ADA, ENDO ($25K)

**Seed: $2.5M (Months 13-24)**
- Team: 12 FTEs ($1.2M)
- Clinical studies: Multi-site validation ($300K)
- FDA submission: 510(k) preparation ($400K)
- Sales & Marketing: Conference presence, ABM ($400K)
- Infrastructure: Scale for enterprise ($200K)

**Series A: $8M (Months 25-48)**
- Team: 40 FTEs ($4M)
- Commercial: Sales team, expansion ($2M)
- R&D: Enterprise features, thyroid CV ($1.5M)
- Regulatory: Reimbursement pathway ($500K)

### 15.2 Milestones by Round

**Pre-Seed → Seed:**
- 10 paying practices
- FDA 510(k) submission prepared
- Hypoglycemia prediction validated
- $100K ARR

**Seed → Series A:**
- 50 paying practices
- FDA clearance received
- $500K ARR
- Enterprise pilot launched

**Series A → Series B:**
- 200 paying practices
- $2M ARR
- Reimbursement coverage secured
+ National health system contracts

---

## 16. Success Metrics

### 16.1 Product Metrics

| Metric | Month 6 | Month 12 | Month 24 | Month 36 |
|--------|---------|----------|----------|----------|
| Active Practices | 5 | 15 | 75 | 200 |
| Active Physicians | 10 | 45 | 225 | 600 |
| Patients Monitored | 500 | 5,000 | 25,000 | 100,000 |
| CGM Reports Generated | 1,000 | 20,000 | 200,000 | 1,000,000 |
| Hypoglycemia Alerts | 100 | 5,000 | 50,000 | 250,000 |

### 16.2 Business Metrics

| Metric | Month 6 | Month 12 | Month 24 | Month 36 |
|--------|---------|----------|----------|----------|
| MRR | $0 | $9,000 | $45,000 | $120,000 |
| ARR | $0 | $108,000 | $540,000 | $1,440,000 |
| Net Dollar Retention | - | 100% | 110% | 115% |
| CAC | - | $250 | $200 | $150 |
| LTV | - | $21,600 | $28,800 | $36,000 |

### 16.3 Clinical Metrics

| Metric | Target | Measurement |
|--------|--------|-------------|
| Hypoglycemia Prediction AUC | >0.85 | ROC analysis, quarterly |
| Time-in-Range Improvement | >10% | Baseline vs 3-month |
| CGM Review Time Savings | >50% | Time-motion studies |
| Physician Satisfaction | >4.5/5 | NPS surveys |
| Patient Satisfaction | >4.0/5 | Post-visit surveys |

---

## 17. Decision Framework

### 17.1 Go/No-Go Checklist

**Market Validation:**
- ✅ 10,000+ endocrinologists in US
- ✅ 37M+ diabetes patients, growing
- ✅ CGM adoption accelerating
- ✅ Clear pain point (time savings)

**Technical Feasibility:**
- ✅ CGM data accessible via APIs
- ✅ Time-series ML well-established
- ✅ 8-week MVP achievable
- ⚠️ Insulin dosing liability manageable

**Business Viability:**
- ✅ Clear revenue model
- ✅ High LTV:CAC (86:1)
- ✅ Viral mechanism (conferences)
- ⚠️ Manufacturer competition exists

**Risk Assessment:**
- ⚠️ FDA pathway required for key features
- ⚠️ Insulin dosing requires careful liability management
- ✅ Data security addressed (HIPAA)
- ✅ Differentiation strategy clear

### 17.2 Final Recommendation: **GO**

**Rationale:**
1. **Massive Market:** 87M diabetes/pre-diabetes patients, 50M with thyroid nodules
2. **AI-Native:** CGM time-series = perfect for ML, hypoglycemia prediction = life-saving
3. **Clear ROI:** 50%+ time savings, measurable outcome improvements
4. **Viral Potential:** ADA conferences, "predicted hypoglycemia" stories
5. **Defensible:** Endocrine-specialized, workflow-integrated, multi-device
6. **Urgency:** Diabetes epidemic growing, CGM adoption at tipping point

**Critical Success Factors:**
1. Hire endocrinologists as co-founders/advisors
2. Secure CGM data access early (partnerships)
3. Lead with hypoglycemia prediction (emotional hook)
4. Build ADA/ENDO conference relationships
5. Navigate FDA pathway proactively
6. Maintain clinical safety above all (insulin dosing)

---

## 18. Next Steps

### Immediate Actions (Week 1)

1. **Clinical Partner Recruitment**
   - Contact local endocrinology practices
   - Reach out to academic endocrinology departments
   - Attend local diabetes educator meetings

2. **Technical Setup**
   - Set up HIPAA-compliant AWS environment
   - Apply for Dexcom, Abbott, Medtronic API access
   - Initialize FastAPI project structure

3. **Legal Preparation**
   - Incorporate (Delaware C-Corp)
   - Draft data processing agreements
   - Begin HIPAA compliance documentation

4. **Advisor Outreach**
   - Identify potential endocrinologist advisors
   - Contact regulatory experts
   - Reach out to diabetes technology industry veterans

### MVP Kickoff (Week 2)

1. **Data Collection**
   - Onboard first practice partner
   - Collect initial CGM datasets
   - Establish data pipelines

2. **Model Development**
   - Begin time-series model training
   - Set up ML experimentation framework
   - Define baseline metrics

3. **Dashboard Prototype**
   - Basic CGM visualization
   - Alert configuration UI
   - Report generation templates

---

## Appendix

### A. CGM Data Dictionary

| Field | Type | Description | Source |
|-------|------|-------------|--------|
| timestamp | datetime | Reading time | Device |
| glucose_value | mg/dL | Glucose concentration | Device |
| device_type | enum | dexcom/abbott/medtronic | User |
| patient_id | UUID | De-identified patient ID | System |

### B. TI-RADS Classification Reference

| Category | TR Level | Malignancy Risk |
|----------|----------|-----------------|
| Benign | 1 | <2% |
| Not Suspicious | 2 | <2% |
| Mildly Suspicious | 3 | 5% |
| Moderately Suspicious | 4 | 5-20% |
| Highly Suspicious | 5 | >20% |

### C. Key References

1. American Diabetes Association. Standards of Care in Diabetes. 2024.
2. FDA. Software as a Medical Device (SaMD): Clinical Evaluation. 2023.
3. ACR TI-RADS Committee. ACR Thyroid Imaging, Reporting and Data System (TI-RADS). 2024.
4. Dexcom Clarity User Data Analysis, 2023.
5. CDC. National Diabetes Statistics Report, 2024.

---

**Document Status:** Complete
**Next Review:** After MVP pilot completion (Week 8)
**Owner:** Clinical Product Team

